Edition:
United Kingdom

Alimera Sciences Inc (ALIM.OQ)

ALIM.OQ on NASDAQ Stock Exchange Global Market

1.22USD
23 Jan 2018
Change (% chg)

$0.06 (+5.17%)
Prev Close
$1.16
Open
$1.17
Day's High
$1.22
Day's Low
$1.16
Volume
7,358
Avg. Vol
27,679
52-wk High
$1.71
52-wk Low
$1.11

Chart for

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 2.27
Market Cap(Mil.): $95.64
Shares Outstanding(Mil.): 69.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital

* ALIMERA SCIENCES INC- ENTERED INTO A $40 MILLION TERM LOAN AGREEMENT WITH SOLAR CAPITAL LTD

08 Jan 2018

BRIEF-Alimera Sciences Inc reports qtrly loss per share ‍$0.08​

* Alimera Sciences Inc reports third quarter 2017 financial results

01 Nov 2017

BRIEF-Alimera Sciences files for mixed shelf of up to $100 mln‍​

* Alimera Sciences Inc files for mixed shelf of up to $100 million – SEC filing ‍​ Source text - (http://bit.ly/2yCWftF) Further company coverage:

23 Oct 2017

BRIEF-Alimera Sciences ‍announces Iluvien now available in Ireland​

* Alimera Sciences Inc - ‍Announces Iluvien now available in Ireland​ Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Alimera Sciences signs agreement for distribution of Iluvien in France

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in France

29 Aug 2017

BRIEF-Alimera Sciences Q2 ‍net loss per share $0.04​

* Alimera Sciences reports second quarter 2017 financial results

02 Aug 2017

BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment

* Alimera Sciences announces real-world audit data supporting the positive benefits of iluvien treatment

25 Jul 2017

Earnings vs. Estimates